All posts

VitalHub should hit $5.00, says Beacon Securities

Gabriel Leung of Beacon Securities is still feeling good about VitalHub (VitalHub Stock Quote, Chart, News, Analysts, Financials TSXV:VHI), maintaining a “Buy” rating and $5/share target price for a projected return of 69 per cent in an update to clients on Friday.

Founded in 2015 and headquartered in Toronto, VitalHub develops technology solutions for health and human service providers in the hospital, regional health authority, mental health, long term care, home health and community and social service sectors in Canada, the United Kingdom and the United States.

Leung’s latest analysis comes after VitalHub announced the acquisition of Beautiful Information Limited, a private operation based in the United Kingdom that offers unique real-time information to NHS trusts to help them plan and resource clinical services to meet hourly fluctuations in patient flow.

Leung expects the company’s platform to complement VitalHub’s existing patient flow and operational visibility product offerings, including those from its acquisitions of Alamac and Transforming Systems.

“While this is a relatively small tuck-in acquisition, it does both strengthen VitalHub’s product and customer footprint in the UK, which we believe could be a catalyst to help the company achieve even greater market share,” Leung said.

Beautiful Information was founded as the first NHS/private partnership of its kind, with support from the Kent Surrey Sussex Academic Health Science Network, the East Kent Hospitals University NHS Foundation Trust, and the Ashford St Peters NHS Foundation Trust.

All told, VitalHub is paying £1.55 million for Beautiful Information Limited, including £1,386,059 in cash and the rest spread out over 90,000 shares at an approximate value of $3.03/share. Post-acquisition, Leung estimates the company still has approximately $13.3 million in cash available, along with a $10 million unused debt facility and ARR of approximately $23 million.

From a valuation standpoint, VitalHub paid 1.6x revenue or 2.6x recurring revenue.

As of December 31, Beautiful Information had generated TTM revenue of £1 million, with 60 per cent of that figure being recurring revenue.

“Adding Beautiful Information’s solutions to our existing suite of Patient Flow and operational visibility products will serve to increase our customer base, while expanding our technology and advisory capabilities,” said Dan Matlow, CEO of VitalHub in the company’s January 27 press release. “The BI team brings extensive healthcare data expertise across the NHS and when combined with our existing Alamac and Transforming Systems products, creates strong synergies that position VitalHub as the leader in the UK for these types of solutions.”

In leaving his financial estimates on VitalHub unchanged, Leung believes the company will experience decent growth over the next couple years, forecasting revenue of $24.4 million in 2021 to imply a year-over-year increase of 76.8 per cent. In 2022, Leung forecasts revenue of $29 million to imply year-over-year growth of 18.9 per cent.

In terms of valuation, Leung forecasts the EV/Revenue multiple to drop from the reported 7.1x in 2020 to a projected 4x in 2021, then to a projected 3.3x in 2022.

Meanwhile, Leung forecasts a double in the company’s EBITDA in 2021, with the $4.6 million estimate implying a margin of 18.9 per cent for 2021. In 2022, the implied margin grows to 21.4 per cent with an estimate of $6.2 million, with Leung also noting the potential for the company to drive additional operating leverage to produce margins between 25 and 30 per cent as the company looks to scale its recurring revenue base.

From a valuation standpoint, Leung projects the EV/EBITDA multiple to drop from the reported 42.8x in 2020 to a projected 21.3x in 2021, then dropping off again to a projected 16x in 2022.

VitalHub’s stock has yielded a small return of 3.1 per cent over the last 12 months, though it has dropped 8.2 per cent from where it began 2022. VitalHub reached a 52-week high of $3.71/share on June 3, a gain from its 52-week low of $2.72/share on February 26.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: vhi
Geordie Carragher

Geordie Carragher is a staff writer for Cantech Letter

Recent Posts

SSTI is a buy, Roth says

Its first quarter results are in the book and Roth MKM analyst Richard K Baldry is still bullish on SoundThinking… [Read More]

7 hours ago

GLXY wins price target raise at ATB Capital

Following the company's first quarter results, ATB Capital Markets analyst Martin Toner has raised his price target on Galaxy Digital… [Read More]

15 hours ago

Paradigm cuts price target on TTNM

Following first quarter results he describes as "mixed" Paradigm Capital analyst Alexandra Ricci has cut her price target on Titanium… [Read More]

17 hours ago

Buy ATS ahead of Q4 earnings, Stifel says

Ahead of the company's fourth quarter earnings report, due May 16, Stifel analyst Justin Keywood says ATS Corp (ATS Corp… [Read More]

2 days ago

Ormat Technologies is a buy, Roth says

Its first quarter results are in the books and Roth MKM analyst Justin Clare thinks there is money to be… [Read More]

2 days ago

Cannabist stock is a buy, Beacon says

Beacon analyst Russell Stanley says the most recent results were better than expected for The Cannabist Company (The Cannabist Company… [Read More]

2 days ago